The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
BAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control
Open accessAbstract
Obesity is a leading cause of preventable death worldwide. Despite this, current strategies for the treatment of obesity remain ineffective at achieving long‐term weight control. This is due, in part, to difficulties in identifying tolerable and efficacious small molecules or biologics capable of regulating systemic nutrient homeostasis. Here, we demonstrate that BAM15, a mitochondrially targeted small molecule protonophore, stimulates energy expenditure and glucose and lipid metabolism to protect against diet‐induced obesity. Exposure to BAM15 in vitro enhanced mitochondrial respiratory kinetics, improved insulin action, and stimulated nutrient uptake by sustained activation of AMPK. C57BL/6J mice treated with BAM15 were resistant to weight gain. Furthermore, BAM15‐treated mice exhibited improved body composition and glycemic control independent of weight loss, effects attributable to drug targeting of lipid‐rich tissues. We provide the first phenotypic characterization and demonstration of pre‐clinical efficacy for BAM15 as a pharmacological approach for the treatment of obesity and related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 3 BAM15 stimulates insulin signaling and oxidation of glucose and fatty acids in an AMPK‐dependent manner A–D(A) Representative immunoblots and (B) quantitative analysis of AKT (1 μM insulin: P = 0.038), (C) AS160 (‐ insulin: P = 0.036, 1 μM insulin: P = 0.0038), and (D) AMPK (‐ insulin: P = 0.018) phosphorylation ± 16‐h BAM15 treatment and 15‐min insulin stimulation (N = 3 per condition) in C2C12 myotubes.E, F(E) Representative immunoblots and quantitative analysis of (F) plasma membrane GLUT4 translocation (P = 0.0139) ± 16‐h BAM15 treatment (N = 3 per condition) in C2C12 myotubes.G, H(G) [3‐3H]glucose uptake ± 16‐h BAM15 treatment and 30‐min insulin stimulation (N = 4 per condition; vehicle versus vehicle + insulin: P = 0.0016, vehicle versus BAM15: P < 0.0001, vehicle versus BAM15 + insulin: P < 0.0001, vehicle + insulin versus BAM15 + insulin: P = 0.0018, BAM15 versus BAM15 + insulin: P = 0.0024) and (H) [1‐14C]palmitate oxidation ± 16‐h BAM15 treatment and 5 mM glucose and 1 mM pyruvate (N = 6 per condition; no glucose/pyruvate: P < 0.0001) in C2C12 myotubes.IRepresentative immunoblot and quantitative analysis (N = 5 per condition; P < 0.0001) of AMPK demonstrating loss of function following transfection with an shAMPK construct in C2C12 myotubes.J, K(J) Representative respirometry plot of intact cells ± shAMPK and 16‐h BAM15 treatment in C2C12 myotubes cells sequentially injected with oligomycin, FCCP, and a cocktail of rotenone and antimycin a (N = 5 per condition) and (K) basal and ATP‐linked respiration, proton leak, maximal uncoupling, and spare respiratory capacity (N = 5 per condition). Basal: shEV versus shEV + BAM15 (P = 0.0317), shEV + BAM15 versus shAMPK (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001). ATP: shEV versus shAMPK + BAM15 (P = 0.0026), shEV + BAM15 versus shAMPK + BAM15 (P = 0.0003), shAMPK versus shAMPK + BAM15 (P = 0.040). Proton leak: shEV versus shEV + BAM15 (P = 0.0052), shAMPK versus shAMPK + BAM15 (P = 0.0394). Maximal: shEV versus shAMPK + BAM15 (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001), shAMPK versus shAMPK + BAM15 (P < 0.0001). Spare capacity: shEV versus shAMPK (P = 0.0028), shEV versus shAMPK + BAM15 (P < 0.0001), shEV + BAM15 versus shAMPK (P < 0.0001), shEV + BAM15 versus shAMPK + BAM15 (P < 0.0001), shAMPK versus shAMPK + BAM15 (P < 0.0001).L[3‐3H]glucose uptake ± shAMPK, 16‐h BAM15 treatment, and 30‐min insulin stimulation in C2C12 myotubes (N = 3 per condition). No insulin: shEV versus shEV + BAM15 (P = 0.0001). Insulin: shEV versus shEV + BAM15 (P = 0.0142).M–O(M) Representative immunoblots and quantitative analysis of (N) AKT (shEV + insulin: P = 0.0128, shAMPK ‐ insulin: P = 0.0018, shAMPK + insulin, P = 0.0124), and (O) AS160 (shEV – insulin: P = 0.0283, shEV + insulin: P = 0.0137) phosphorylation ± shAMPK, 16‐h BAM15 treatment, and 15‐min insulin stimulation in C2C12 myotubes (N = 3 per condition).Data information: Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels B, C, D, H, K, L, N, and O were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panel G was assessed by one‐way ANOVA with Tukey's multiple comparisons. Panels F and I were assessed by unpaired Student's t‐test. Source data are available online for this figure.](https://figures.cochat.ai/paper-figures/5202ac49eefd415382e4027f7038a832/bam15mediated-mitochondrial-uncoupling-protects-against-obesity-and-improves-figure-3.jpg)






![Figure 7 Increased skeletal muscle fatty acid oxidation is supported by AMPK‐mediated suppression of lipogenesis in white adipose tissue following treatment with BAM15 A–D(A) Plasma concentrations of non‐esterified fatty acids (NEFAs) (CTRL N = 7, BAM15 N = 8, P = 0.0073), (B) leptin (N = 8 per group, P < 0.0001), (C) GDF15 (N = 7 per group, P = 0.035), and (D) FGF21 (N = 7 per group, P = 0.0026) after 3 weeks of CTRL or BAM15 treatment.E, F(E) Total (basal: P = 0.015) and (F) complete (basal: P = 0.0137) oxidation of 200 μM [1‐14C]palmitate to CO2 from mixed gastrocnemius muscle homogenates (N = 7 per group).GRoutine (R) oxygen flux, leak (L), OXPHOS (P), and ETC. (E) capacity in permeabilized mixed gastrocnemius fibers (N = 6 per group). PM: pyruvate and malate, ADP: adenosine diphosphate, GS: glutamate and succinate, Tm: tetramethyl‐p‐phenylenediamine, PalM: palmitoylcarnitine and malate, Oct: octanoylcarnitine, and Dur: duroquinol.H–K(H) Representative immunoblots of phosphorylated and total AMPK and ACC from iWAT, and mixed gastrocnemius muscle and (I‐K) densitometric quantification (N = 4 per group; iWAT p‐AMPKT172: P = 0.0186, iWAT p‐ACCS79: P = 0.0083, mixed gastrocnemius p‐AMPKT172: P = 0.0286).L–NmRNA expression of transcriptional regulators of lipogenesis and lipolysis in iWAT (N = 7 per group). Srebf1 (P < 0.0001), Mlxipl (P = 0.0018), Scd1 (P < 0.0001), FASN (P = 0.0009), LIPE (P = 0.0015), Pnpla2 (P < 0.0001), PPARg (P < 0.0001).Data information: Data are shown as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.01, ****P < 0.001. Panels E, F, and G were assessed by two‐way repeated‐measures ANOVA with Tukey's multiple comparisons. Panels A, B, C, D, I, J, K, L, M, and N were assessed by an unpaired Student's t‐test. Source data are available online for this figure.](https://figures.cochat.ai/paper-figures/7de18429f2d24bd78bf5737fea9ecfac/bam15mediated-mitochondrial-uncoupling-protects-against-obesity-and-improves-figure-7.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BAM15, a mitochondrially targeted protonophore with wide tolerability, stimulated energy expenditure and glucose and lipid metabolism to prevent diet-induced obesity in mice. Besides, BAM15 improved glycemic control and reduced adiposity through insulin signaling and oxidation of glucose and fatty acids in an AMPK-dependent manner [134].”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Child abuse: Adolescent records vs. adult recall
Femina, D. D., Yeager, C. A., & Lewis, D. O. (1990) · Child Abuse & Neglect · doi:10.1016/0145-2134(90)90033-p · Cited by 8,820
Finkelstein, E. A., Trogdon, J. G., Cohen, J. W., & Dietz, W. (2009) · Health Affairs · doi:10.1377/hlthaff.28.5.w822 · Cited by 2,957
Assessing mitochondrial dysfunction in cells
Brand, M. D., & Nicholls, D. G. (2011) · Biochemical Journal · doi:10.1042/bj20110162 · Cited by 2,405
Hematoxylin and Eosin Staining of Tissue and Cell Sections
Fischer, A. H., Jacobson, K. A., Rose, J., & Zeller, R. (2008) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot4986 · Cited by 2,128
Li, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, E., Shyy, J. Y.-J., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.009 · Cited by 1,778
Loss of stearoyl–CoA desaturase-1 function protects mice against adiposity
Ntambi, J. M., Miyazaki, M., Stoehr, J. P., Lan, H., Kendziorski, C. M., Yandell, B. S., Song, Y., Cohen, P., Friedman, J. M., & Attie, A. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132384699 · Cited by 1,095
Reduced Food Intake and Body Weight in Mice Treated with Fatty Acid Synthase Inhibitors
Loftus, T. M., Jaworsky, D. E., Frehywot, G. L., Townsend, C. A., Ronnett, G. V., Lane, M. D., & Kuhajda, F. P. (2000) · Science · doi:10.1126/science.288.5475.2379 · Cited by 1,004
Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight Loss
Cohen, P., Miyazaki, M., Socci, N. D., Hagge-Greenberg, A., Liedtke, W., Soukas, A. A., Sharma, R., Hudgins, L. C., Ntambi, J. M., & Friedman, J. M. (2002) · Science · doi:10.1126/science.1071527 · Cited by 821
Cited by
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Sarcopenic obesity: Emerging mechanisms and therapeutic potential
Axelrod, C. L., Dantas, W. S., & Kirwan, J. P. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155639 · Cited by 204
Self-citationThe critical role of oxidative stress in sarcopenic obesity
Gonzalez, A., Simon, F., Achiardi, O., Vilos, C., Cabrera, D., & Cabello-Verrugio, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/4493817 · Cited by 79
Consumption and Metabolism of Extracellular Pyruvate by Cultured Rat Brain Astrocytes
Denker, N., Harders, A. R., Arend, C., & Dringen, R. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03831-6 · Cited by 22
“1 3 myotubes [61] and BAM15-treated mouse liver mitochondria [50].”
BackgroundTargeting skeletal muscle mitochondrial health in obesity
Pileggi, C. A., Hooks, B. G., McPherson, R., Dent, R. R. M., & Harper, M.-E. (2022) · Clinical Science · doi:10.1042/cs20210506 · Cited by 21
Metadata
- Authors
- Axelrod, C. L., King, W. T., Davuluri, G., Noland, R. C., Hall, J., Hull, M., Dantas, W. S., Zunica, E. R., Alexopoulos, S. J., Hoehn, K. L., Langohr, I., Stadler, K., Doyle, H., Schmidt, E., Nieuwoudt, S., Fitzgerald, K., Pergola, K., Fujioka, H., Mey, J. T., Fealy, C., Mulya, A., Beyl, R., Hoppel, C. L., & Kirwan, J. P.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cleveland Clinic (US)
- UNSW Sydney (AU)
- Louisiana State University (US)
- Case Western Reserve University (US)
- Corresponding author
- Kirwan, John P
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-06-10
- Volume
- 12
- Issue
- 7
- Pages
- e12088-e12088
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7338798
- OpenAlex
- W3032939189
- Cited by
- 89
- References
- 65
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 8 · 2023: 18 · 2022: 12 · 2021: 16 · 2020: 3
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Civil War Book Review (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (DK108089, DK103860, DK115749, DK072476)
- Department of Health|National Health and Medical Research Council (GNT1163903)
- HHS|NIH|National Institute of General Medical Sciences (GM103528, GM104940)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- BAM15, mitochondrial uncoupling, protonophores, diet-induced obesity, energy expenditure, glucose metabolism, lipid metabolism, insulin sensitivity, AMPK activation, mitochondrial respiration, glycemic control, body composition, obesity treatment
- MeSH terms
- Glycemic Control, Animals, Energy Metabolism, Glucose, Insulin Resistance, Male, Mice, Inbred C57BL, Mitochondria, Obesity, Uncoupling Agents, Mice, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control. https://app.cochat.ai/papers/10.15252/emmm.202012088
- The paper
- Axelrod, C. L., King, W. T., Davuluri, G., Noland, R. C., Hall, J., Hull, M., Dantas, W. S., Zunica, E. R., Alexopoulos, S. J., Hoehn, K. L., Langohr, I., Stadler, K., Doyle, H., Schmidt, E., Nieuwoudt, S., Fitzgerald, K., Pergola, K., Fujioka, H., Mey, J. T., . . . Kirwan, J. P. (2020). BAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202012088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.